A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease

[1]  L. Nathanson,et al.  α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription , 2020, iScience.

[2]  Guglielmo Foffani,et al.  A Cortical Pathogenic Theory of Parkinson’s Disease , 2018, Neuron.

[3]  P. Jensen,et al.  ELISA method to detect α-synuclein oligomers in cell and animal models , 2018, PloS one.

[4]  J. Trojanowski,et al.  Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs , 2017, Neurobiology of Disease.

[5]  C. Kaminski,et al.  α-Synuclein - Regulator of Exocytosis, Endocytosis, or Both? , 2017, Trends in cell biology.

[6]  C. Richter-Landsberg,et al.  Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss , 2017, Acta neuropathologica communications.

[7]  H. Braak,et al.  Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff , 2017, Journal of Parkinson's disease.

[8]  Mark Ellisman,et al.  Parkinson Sac Domain Mutation in Synaptojanin 1 Impairs Clathrin Uncoating at Synapses and Triggers Dystrophic Changes in Dopaminergic Axons , 2017, Neuron.

[9]  M. Behari,et al.  Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism. , 2016, Parkinsonism & related disorders.

[10]  S. Dutertre,et al.  Neurite analyzer: An original Fiji plugin for quantification of neuritogenesis in two-dimensional images , 2016, Journal of Neuroscience Methods.

[11]  Joana S. Ferreira,et al.  Multiple domains in the C-terminus of NMDA receptor GluN2B subunit contribute to neuronal death following in vitro ischemia , 2016, Neurobiology of Disease.

[12]  Suzanne N. Haber,et al.  Corticostriatal circuitry , 2016, Dialogues in clinical neuroscience.

[13]  M. Hinds,et al.  Human β-defensin 3 contains an oncolytic motif that binds PI(4,5)P2 to mediate tumour cell permeabilisation , 2015, Oncotarget.

[14]  Richard Nicholas,et al.  Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space , 2015, Neuropathology and applied neurobiology.

[15]  Y. Smith,et al.  Morphological changes of glutamatergic synapses in animal models of Parkinson’s disease , 2015, Front. Neuroanat..

[16]  J. Gruschus.  Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson’s Disease , 2015, PloS one.

[17]  F. Benfenati,et al.  α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons , 2015, Journal of Cell Science.

[18]  T. Jovin,et al.  Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons , 2015, Cell Death and Disease.

[19]  P. De Camilli,et al.  Detection and manipulation of phosphoinositides. , 2015, Biochimica et biophysica acta.

[20]  Suyong Choi,et al.  PIP kinases define PI4,5P₂signaling specificity by association with effectors. , 2015, Biochimica et biophysica acta.

[21]  J. Grigoletto,et al.  Lysine residues at the first and second KTKEGV repeats mediate α-Synuclein binding to membrane phospholipids , 2014, Neurobiology of Disease.

[22]  F. Gage,et al.  Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. , 2014, Brain : a journal of neurology.

[23]  H. Bergman,et al.  Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease , 2014, Neurology.

[24]  K. Kalil,et al.  Branch management: mechanisms of axon branching in the developing vertebrate CNS , 2013, Nature Reviews Neuroscience.

[25]  J. Liao,et al.  Feedback regulation of receptor-induced Ca2+ signaling mediated by E-Syt1 and Nir2 at endoplasmic reticulum-plasma membrane junctions. , 2013, Cell reports.

[26]  Sima Lev,et al.  The phosphatidylinositol‐transfer protein Nir2 binds phosphatidic acid and positively regulates phosphoinositide signalling , 2013, EMBO reports.

[27]  Robert Chen,et al.  Motor Cortical Plasticity in Parkinson’s Disease , 2013, Front. Neurol..

[28]  S. Pappatà,et al.  Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early‐Onset Parkinsonism , 2013, Human mutation.

[29]  Vladimir Makarov,et al.  The Sac1 Domain of SYNJ1 Identified Mutated in a Family with Early‐Onset Progressive Parkinsonism with Generalized Seizures , 2013, Human mutation.

[30]  Y. Yamauchi,et al.  Phosphatidylinositol 4-phosphate 5-kinase β regulates growth cone morphology and Semaphorin 3A-triggered growth cone collapse in mouse dorsal root ganglion neurons , 2013, Neuroscience Letters.

[31]  Kindiya D. Geghman,et al.  Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment , 2013, Experimental Neurology.

[32]  J. Bolam,et al.  Living on the edge with too many mouths to feed: Why dopamine neurons die , 2012, Movement disorders : official journal of the Movement Disorder Society.

[33]  Y. Yaari,et al.  α‐Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease , 2012, Brain pathology.

[34]  H. Braak,et al.  Lewy pathology and neurodegeneration in premotor Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[35]  N. Hirokawa,et al.  Phosphatidylinositol 4-phosphate 5-kinase alpha (PIPKα) regulates neuronal microtubule depolymerase kinesin, KIF2A and suppresses elongation of axon branches , 2012, Proceedings of the National Academy of Sciences.

[36]  A. Kakita,et al.  Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease , 2011, Neuropathology and applied neurobiology.

[37]  B. Hochner,et al.  A new perspective on the organization of an invertebrate brain , 2011 .

[38]  John T. Schmidt,et al.  GAP43 phosphorylation is critical for growth and branching of retinotectal arbors in zebrafish , 2010, Developmental neurobiology.

[39]  Ann Saada,et al.  The Transgenic Overexpression of α-Synuclein and Not Its Related Pathology Associates with Complex I Inhibition* , 2010, The Journal of Biological Chemistry.

[40]  J. Meldolesi,et al.  {alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. , 2009, Molecular biology of the cell.

[41]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[42]  H. Braak,et al.  Neuroanatomy and pathology of sporadic Parkinson's disease. , 2008, Advances in anatomy, embryology, and cell biology.

[43]  Terrence M Wright,et al.  Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP‐treated monkey model of parkinsonism , 2008, The European journal of neuroscience.

[44]  E. Hirsch,et al.  Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease , 2007, Neurobiology of Aging.

[45]  Derek Toomre,et al.  Two synaptojanin 1 isoforms are recruited to clathrin-coated pits at different stages , 2006, Proceedings of the National Academy of Sciences.

[46]  Tobias Meyer,et al.  Rapid Chemically Induced Changes of PtdIns(4,5)P2 Gate KCNQ Ion Channels , 2006, Science.

[47]  H. Braak,et al.  Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered , 2006, Movement disorders : official journal of the Movement Disorder Society.

[48]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[49]  D. Kirik,et al.  Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression , 2006, Neurobiology of Disease.

[50]  Hong Zhang,et al.  FARP2 triggers signals for Sema3A-mediated axonal repulsion , 2005, Nature Neuroscience.

[51]  W. Denk,et al.  Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Kuramoto,et al.  Presynaptic localization of an AMPA‐type glutamate receptor in corticostriatal and thalamostriatal axon terminals , 2004, The European journal of neuroscience.

[53]  B. Gähwiler,et al.  Selective neurofilament (SMI-32, FNP-7 and N200) expression in subpopulations of layer V pyramidal neurons in vivo and in vitro. , 2004, Cerebral cortex.

[54]  Jonathan Salcedo,et al.  Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein , 2004, The Journal of Neuroscience.

[55]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[56]  M. Roth,et al.  ARNO and ARF6 regulate axonal elongation and branching through downstream activation of phosphatidylinositol 4-phosphate 5-kinase alpha. , 2003, Molecular biology of the cell.

[57]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[58]  Erwan Bezard,et al.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.

[59]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[60]  E. Myers,et al.  Finishing a whole-genome shotgun: Release 3 of the Drosophila melanogaster euchromatic genome sequence , 2002, Genome Biology.

[61]  Pietro De Camilli,et al.  Recruitment and regulation of phosphatidylinositol phosphate kinase type 1γ by the FERM domain of talin , 2002, Nature.

[62]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[63]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[64]  B. Eickholt,et al.  Essential Role of Type Iα Phosphatidylinositol 4-Phosphate 5-Kinase in Neurite Remodeling , 2002, Current Biology.

[65]  M. Schäfer,et al.  Identification of the Differentiation-Associated Na+/PI Transporter as a Novel Vesicular Glutamate Transporter Expressed in a Distinct Set of Glutamatergic Synapses , 2002, The Journal of Neuroscience.

[66]  J. George,et al.  The synucleins , 2001, Genome Biology.

[67]  B. Giros,et al.  The Existence of a Second Vesicular Glutamate Transporter Specifies Subpopulations of Glutamatergic Neurons , 2001, The Journal of Neuroscience.

[68]  C. Specht,et al.  Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice , 2001, BMC Neuroscience.

[69]  J. Storm-Mathisen,et al.  The Expression of Vesicular Glutamate Transporters Defines Two Classes of Excitatory Synapse , 2001, Neuron.

[70]  N. Nathanson,et al.  The M1 Receptor Is Required for Muscarinic Activation of Mitogen-activated Protein (MAP) Kinase in Murine Cerebral Cortical Neurons* , 2001, The Journal of Biological Chemistry.

[71]  E. Masliah,et al.  Reduced Neuritic Outgrowth and Cell Adhesion in Neuronal Cells Transfected with Human α-Synuclein , 2001, Molecular and Cellular Neuroscience.

[72]  Noam E Ziv,et al.  Assembly of New Individual Excitatory Synapses Time Course and Temporal Order of Synaptic Molecule Recruitment , 2000, Neuron.

[73]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[74]  F. Walsh,et al.  Neurite Outgrowth Stimulated by Neural Cell Adhesion Molecules Requires Growth-Associated Protein-43 (GAP-43) Function and Is Associated with GAP-43 Phosphorylation in Growth Cones , 1998, The Journal of Neuroscience.

[75]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[76]  J. Bos,et al.  B-50/GAP-43-induced formation of filopodia depends on Rho-GTPase. , 1998, Molecular biology of the cell.

[77]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[78]  Tobias Meyer,et al.  Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells , 1998, Current Biology.

[79]  P. Calabresi,et al.  Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum , 1997, Neuroscience & Biobehavioral Reviews.

[80]  P. Caroni,et al.  The motility-associated proteins GAP-43, MARCKS, and CAP-23 share unique targeting and surface activity-inducing properties. , 1997, Experimental cell research.

[81]  M. Starr.  Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease , 1995, Synapse.

[82]  R. Kötter.  Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum , 1994, Progress in Neurobiology.

[83]  D. Graham,et al.  β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injury , 1993, Neuroscience Letters.

[84]  A. Graybiel.  Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.

[85]  A. Grace,et al.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.

[86]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[87]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[88]  D L Price,et al.  Parkinson's disease , 1985, Neurology.

[89]  B. Gomperts,et al.  The dependence on Ca2+ of phosphatidylinositol breakdown and enzyme secretion in rabbit neutrophils stimulated by formylmethionyl-leucylphenylalanine or ionomycin. , 1981, The Biochemical journal.

[90]  R. Sturrock.  MYELINATION OF THE MOUSE CORPUS CALLOSUM , 1980, Neuropathology and applied neurobiology.

[91]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[92]  M. Bastiani,et al.  Overexpression of PPK-1, the Caenorhabditis elegans Type I PIP kinase, inhibits growth cone collapse in the developing nervous system and causes axonal degeneration in adults. , 2008, Developmental biology.

[93]  M. Chesselet,et al.  Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[94]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[95]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[96]  B. Eickholt,et al.  Essential role of type I(alpha) phosphatidylinositol 4-phosphate 5-kinase in neurite remodeling. , 2002, Current biology : CB.